Withaferin A Increases the Effectiveness of Immune Checkpoint Blocker for the Treatment of Non-Small Cell Lung Cancer

Withaferin A Increases the Effectiveness of Immune Checkpoint Blocker for the Treatment of Non-Small Cell Lung Cancer

Treatment of late-stage lung cancers remains challenging with a five-year survival rate of 8%. Immune checkpoint blockers (ICBs) revolutionized the treatment of non-small cell lung cancer (NSCLC) by reactivating anti-tumor immunity. Despite achieving durable responses, ICBs are effective in only 20%...

Full description

Bibliographic Details
Main Authors: Roukiah Khalil, Ryan J. Green, Kavya Sivakumar, Payal Varandani, Srinivas Bharadwaj, Shyam S. Mohapatra, Subhra Mohapatra
Format: Article
Language:English
Published: MDPI AG 2023-06-01
Series:Cancers
Subjects:
PD-L1
immune checkpoint blockers
immunotherapy
Withaferin A
combination therapy
lung cancer
Online Access:https://www.mdpi.com/2072-6694/15/12/3089

Similar Items

Similar Items